Newsroom
Sorted by: Latest
-
WTOP News Awards MPR a Top Workplaces 2026 Honor
ALEXANDRIA, Va.--(BUSINESS WIRE)--MPR Associates has been awarded a Top Workplaces 2026 honor by WTOP News....
-
Accord Announces Voting Results of Annual Meeting
TORONTO--(BUSINESS WIRE)--Accord Announces Voting Results of Annual Meeting...
-
Investigation Alert: BFA Law Announces It Is Investigating Barry Diller’s Bid to Buy MGM Resorts International (MGM) for $48.30 Per Share
NEW YORK--(BUSINESS WIRE)--BFA Law Announces it is Investigating Barry Diller’s bid to buy MGM Resorts International (MGM) for $48.30 per share...
-
The Rice Family Foundation to Support Local Area Non-Profit Organizations
HANOVER, Pa.--(BUSINESS WIRE)--The Rice Family Foundation (“Foundation”) was established in 2017 by Michael & Jane Rice and Dylan & Stacie Lissette, third and fourth-generation members of the Utz Brands, Inc. family. The Foundation was established to provide leadership and support for the education, health and well-being of families in Hanover, Pennsylvania, and the surrounding communities. Using funds granted by the Foundation, The Rice Family Foundation supports eligible non-profit or...
-
NEA Names Philip Chopin Managing Director, Head of Europe and Promotes Two Investors
MENLO PARK, Calif.--(BUSINESS WIRE)--Global venture capital firm New Enterprise Associates, Inc. (NEA) today announced several promotions across the firm's investment team, including the appointment of Philip Chopin as Managing Director, Head of Europe. The firm also promoted technology investors Ayush Goradia and James Kaplan to Principal. "Philip has played an instrumental role in establishing our London office and deepening the firm's presence in Europe," said Tony Florence, Co-CEO, NEA. "He...
-
AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts
TALLAHASSEE, Fla.--(BUSINESS WIRE)--AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts...
-
Harvest Care Medical Completes DEA Registration Across Entire Cannabis Operations
BRIDGEPORT, W. Va.--(BUSINESS WIRE)--Harvest Care Medical today announced the successful completion of its U.S. Drug Enforcement Administration (DEA) registration process for all of its licensed cannabis operations, including 10 dispensaries, one cultivation facility, and one processing facility. The milestone further strengthens the company’s regulatory compliance framework and positions Harvest Care Medical for continued operational excellence and future growth. The completion of DEA registra...
-
Over 100 long-term care workers rally for better working conditions and wages as for-profit corporation stonewalls in negotiations
Markham, ON--(BUSINESS WIRE)--On Monday, June 29, over 100 long-term care workers from across the province boarded buses to hold a rally at Extendicare’s head office in Markham. Eight CUPE local unions representing 1,100 long-term care staff are currently in bargaining with Extendicare. The employees are calling on the for-profit corporation to address chronic understaffing, low wages and inadequate benefits - issues directly tied to resident care. Extendicare previously withdrew from talks in...
-
Samsung Bioepis gibt positive vorläufige Phase-1- und Phase-3-Daten für SB27 bekannt, ein geplantes Biosimilar zu Keytruda (Pembrolizumab)
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. gab heute bekannt, dass die Phase-1- und Phase-3-Studien zu SB27, einem geplanten Biosimilar zu Keytruda1 (Pembrolizumab), ihre primären Endpunkte erreicht haben. „Wir freuen uns, vorläufige Ergebnisse aus den Phase-1- und Phase-3-Studien zu SB27, unserem Pembrolizumab-Biosimilar-Kandidaten, bekannt zu geben. Diese positiven Topline-Ergebnisse untermauern unsere wissenschaftliche Kompetenz und unsere Führungsrolle in der Entwicklung von...
-
Samsung Bioepis anuncia dados preliminares positivos das Fases 1 e 3 para o SB27, um biossimilar proposto para o Keytruda (Pembrolizumabe)
INCHEON, Coreia--(BUSINESS WIRE)--A Samsung Bioepis Co., Ltd. anunciou hoje que os estudos de Fase 1 e Fase 3 sobre o SB27, um biossimilar proposto para o Keytruda1 (pembrolizumabe), atingiram seus desfechos primários. “Temos o prazer de anunciar os resultados preliminares dos estudos de Fase 1 e Fase 3 do SB27, nosso candidato a biossimilar de pembrolizumabe. Esses resultados positivos iniciais reforçam nossa expertise científica e nossa liderança no desenvolvimento de biossimilares”, afirmou...